WuXi Biologics (HK:2269), a China-based global Contract Research, Development, and Manufacturing Organisation (CRDMO), announced on Thursday that it has received AAA ESG rating from Morgan Stanley Capital International (MSCI) for the third consecutive year.

According to WuXi Biologics, this top-tier rating by MSCI recognises the company's outstanding ESG performance and acknowledges its strong leadership in advocating sustainability, particularly in the key areas of climate change, product safety and quality, human capital development, and corporate governance.

Covering more than 17,000 issuers and 999,000 securities worldwide, MSCI ESG Ratings provide insights for investment decision-making as they focus on measuring companies' resilience to financially relevant, industry-specific sustainability risks and opportunities.

In line with the United Nations Sustainable Development Goals, WuXi Biologics says that it has been actively engaged with the United Nations Global Compact (UNGC) and the Pharmaceutical Supply Chain Initiative (PSCI). Recently, the company's new near-term and net-zero greenhouse gas emissions-reduction target matrix has been approved by the Science Based Targets initiative (SBTi).